Business
MedX(R) Announces Agreement with Technology4Medicine To Expand Product Distribution in the U.S. Market
Technology4Medicine to have exclusive U.S. distribution rights for MedX lasers in the dental, der...
About this update from Medx Health Corp.
[{"type":"text","content":"\n\n\n\nTechnology4Medicine to have exclusive U.S. distribution rights for MedX\n\n\nlasers in the dental, dermatology, plastic surgery and anti-aging\n\n\nmarkets; MedX will continue direct distribution for the U.S.\n\n\nRehabilitation Market\n\n\nMISSISSAUGA, ON, July 15 /CNW/ - MedX Health Corp. (TSXV: MDX) today\nannounced an exclusive distribution agreement with Technology4Medicine, a\nnewly formed laser company based in San Clemente, CA, for the U.S. dental,\ndermatology, plastic surgery and anti-aging markets. Technology4Medicine will\nsell MedX Health's newest laser product, Oralase(TM) immediately upon\nclearances from the Food and Drug Administration to dental offices. Oralase is\na low level laser therapy (LLLT) exclusively designed for dentists to\nalleviate pain and accelerate tissue repair following dental procedures.\n\n\n"This partnership fulfills a key component of our vision for growth and\nwe are pleased to enter into this agreement with an exciting new company such\nas Technology4Medicine," said Steve Guillen B.Sc., M.B.A., President & CEO,\nMedX Health. "As we move forward with our business plan to become the\nworldwide leader in light technology, MedX is committed to choosing the right\npartners to accelerate product distribution while continuing to develop\nsuperior products and explore new therapeutic opportunities for those\nproducts. We believe that Technology4Medicine is the right partner to\npenetrate the dental and other related markets in the United States through\ntheir specialized, experienced sales staff."\n\n\n"MedX is already well established in the rehabilitation market, offering\ninnovative laser and light therapy products that have successfully treated\npain, sports injuries and other conditions," continued Guillen. "We believe\nour products can offer patients with acute and chronic wounds a non-invasive,\ndrug free solution and we fully intend to pursue these indications\naggressively."\n\n\nThe terms of the agreement include MedX giving Technology4Medicine\nexclusive U.S. rights to sell Oralase and other MedX lasers that may be\napplicable in the dental, dermatology, plastic surgery and anti-aging markets.\nIncreased levels of promotion are expected to cross over into these other\nlarge growth markets.\n\n\n"This agreement helps put Technolo...